Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002675467 | SCV002289563 | likely pathogenic | Ocular cystinosis; Juvenile nephropathic cystinosis; Inborn genetic diseases | 2021-04-02 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has not been reported in the literature in individuals with CTNS-related conditions. This variant is present in population databases (rs767289120, ExAC 0.02%). This sequence change affects a donor splice site in intron 3 of the CTNS gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CTNS are known to be pathogenic (PMID: 9537412, 27102039). |
Fulgent Genetics, |
RCV002052012 | SCV002794547 | likely pathogenic | Ocular cystinosis; Juvenile nephropathic cystinosis; Nephropathic cystinosis | 2021-10-28 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003475282 | SCV004212982 | likely pathogenic | Nephropathic cystinosis | 2023-02-19 | criteria provided, single submitter | clinical testing |